Abbares Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.23 Cr
- Satisfied Charges ₹ 4.47 Cr
- Revenue Growth 36.96%
- Profit Growth 51.29%
- Ebitda 50.63%
- Net Worth 34.64%
- Total Assets 25.10%
About Abbares Pharmaceuticals
Abbares Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 March 2018 (Six years and ten months 3 days old ). Its registered office is in Jodhpur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹4.23 Cr. The company has closed loans amounting to ₹4.47 Cr, as per Ministry of Corporate Affairs (MCA) records.
Company Details
-
Location
Jodhpur, Rajasthan, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U51909RJ2018PTC060761
-
Company No.
060761
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
31 Mar 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Abbares Pharmaceuticals?
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Rajesh Bhardwaj | Director | 31-Mar-2018 | Current |
Preksha Bhardwaj | Director | 15-Jun-2019 | Current |
Seema Bhardwaj | Director | 01-Nov-2021 | Current |
Financial Performance of Abbares Pharmaceuticals.
Abbares Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 36.96% increase. The company also saw a substantial improvement in profitability, with a 51.29% increase in profit. The company's net worth Soared by an impressive increase of 34.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Abbares Pharmaceuticals?
In 2022, Abbares Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹42.31 M
₹44.68 M
Charges Breakdown by Lending Institutions
- Others : 4.18 Cr
- Hdfc Bank Limited : 0.05 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
20 Nov 2023 | Others | ₹3.50 Cr | Open |
18 Oct 2022 | Others | ₹6.80 M | Open |
21 Dec 2021 | Hdfc Bank Limited | ₹0.51 M | Open |
30 Sep 2022 | Others | ₹2.97 Cr | Satisfied |
29 Jan 2021 | Hdfc Bank Limited | ₹1.20 Cr | Satisfied |
How Many Employees Work at Abbares Pharmaceuticals?
Unlock and access historical data on people associated with Abbares Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abbares Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abbares Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.